Literature DB >> 10334375

Carisoprodol (soma): abuse potential and physician unawareness.

R R Reeves1, O S Carter, H B Pinkofsky, F A Struve, D M Bennett.   

Abstract

Carisoprodol is a noncontrolled skeletal muscle relaxant whose active metabolite is meprobamate, a Schedule IV controlled substance. Although several case reports have shown that carisoprodol has abuse potential, it continues to be widely prescribed. The usage patterns of 40 patients who had taken carisoprodol for three or more months (20 of whom had no history of substance abuse and 20 of whom carried a diagnosis of substance abuse or dependence) were reviewed and compared and a survey was conducted to assess physician awareness of the abuse potential of the drug. Findings showed that some patients using carisoprodol for over three months may abuse the medication, especially those individuals with a history of substance abuse. A significant percentage of the physician population is unaware of the potential of carisoprodol for abuse and of its metabolism to meprobamate, a controlled substance. Physicians should exercise caution when prescribing carisoprodol, especially if the patient has a history of substance abuse.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334375     DOI: 10.1300/J069v18n02_05

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  5 in total

1.  Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003.

Authors:  Gudrun Høiseth; Jørgen G Bramness; Asbjørg S Christophersen; Jørg Mørland
Journal:  Int J Legal Med       Date:  2006-11-18       Impact factor: 2.686

Review 2.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

3.  Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain.

Authors:  Corey Witenko; Robin Moorman-Li; Carol Motycka; Kevin Duane; Juan Hincapie-Castillo; Paul Leonard; Christopher Valaer
Journal:  P T       Date:  2014-06

4.  Mass spectrometric analysis of carisoprodol and meprobamate in rat brain microdialysates.

Authors:  Laszlo Prokai; Petr Fryčák; Vien Nguyen; Michael J Forster
Journal:  J Mass Spectrom       Date:  2016-10       Impact factor: 1.982

5.  Carisoprodol abuse in Texas, 1998-2003.

Authors:  Mathias B Forrester
Journal:  J Med Toxicol       Date:  2006-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.